-
Mashup Score: 3
Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however, its use has complicated the diagnosis of non-small cell lung cancer (NSCLC).
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Rare Forms of Lung Cancer - 3 year(s) ago
Years of research into the molecular biology of lung cancer have uncovered the complexities of this deadly disease and what drives it. Today, we know there are several different driver mutations that may be underlying causes of lung cancer, and correctly identifying them is a crucial first step to an accurate diagnosis. We spoke with Jyoti Patel, MD, Professor of Medicine at Northwestern…
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Cancer Research Update: Improving Diagnosis of Rare Forms of Lung Cancer https://t.co/8cRMueHhce https://t.co/2y8cryTWkt
-
-
Mashup Score: 1Rare Forms of Lung Cancer - 3 year(s) ago
Years of research into the molecular biology of lung cancer have uncovered the complexities of this deadly disease and what drives it. Today, we know there are several different driver mutations that may be underlying causes of lung cancer, and correctly identifying them is a crucial first step to an accurate diagnosis. We spoke with Jyoti Patel, MD, Professor of Medicine at Northwestern…
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEW online! Improving Outcomes for Patients with Rare Forms of #LungCancer https://t.co/8cRMueHhce https://t.co/BwNhQvT8ln
-
NEW online: Improving Outcomes for Patients with Rare Forms of #LungCancer Starts at Diagnosis https://t.co/8cRMueHhce #medtwitter #cancertreatment via @NUFeinbergMed https://t.co/apF7gmFfId
-
-
Mashup Score: 0
Researchers at the Children’s Medical Center Research Institute at UT Southwestern (CRI) have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC). These findings could pave the way for new treatments for patients with mutations in two key genes—KRAS and LKB1. Patients whose tumors contain both of these mutations, known as KL tumors, have poor…
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEW online: Researchers Uncover a Potential Treatment for Aggressive Form of #LungCancer https://t.co/JpJo9pkINI #cancertreatment #medtwitter #lcsm via @HHMINEWS https://t.co/CB38ATnQOG
-
-
Mashup Score: 1FDA Approves Cemiplimab-Rwlc for First-Line Advanced NSCLC - 3 year(s) ago
The FDA recently approved the PD-1 inhibitor cemiplimab-rwlc for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score ≥50%), as determined by an FDA-approved test.
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA Update: FDA Approves Cemiplimab-Rwlc for First-Line Advanced Non-Small Cell #LungCancer https://t.co/x6SRMpfmSk #lcsm #cancertreatment #medtwitter via @columbiacancer https://t.co/VXEdXhSJeL
-
-
Mashup Score: 0Potential Combined Drug Therapy for NSCLC - 3 year(s) ago
Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment. Alectinib is a drug commonly used for treating patients with NSCLC.
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#CancerTreatment Update: Potential Combined Drug Therapy for Non-Small Cell #LungCancer https://t.co/M5t6vd8QrQ #medtwitter https://t.co/z2qPxYREaj
-
-
Mashup Score: 0Cases and Quizzes - 3 year(s) ago
Cases and Quizzes focusing on NSCLC
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ThursdayMotivation: Sharpen your knowledge with these free tests from The Bethesda Review of Clinical Oncology: https://t.co/wnw5unP3fW #MedEd #cancer https://t.co/mwnzbDNNjQ
-
-
Mashup Score: 1Immunotherapy Creates Balancing Act for Patients With NSCLC - 3 year(s) ago
The results of a large, retrospective study of patients who received a form of immunotherapy for non-small cell lung cancer (NSCLC) revealed that patients may get more than one immune-related side effect, and identified a correlation between these multisystem immune-related adverse events (irAEs) and improved patient survival.
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Immunotherapy Creates Balancing Act for Patients With Non-Small Cell #LungCancer https://t.co/0p7X8HDcFv #lcsm #cancertreatment #medtwitter via @DrJNaidoo @JohnsHopkins https://t.co/XPXy3gIRL3
-
-
Mashup Score: 0Lung Cancer Resource Center - 3 year(s) ago
Timely studies, news, quizzes, and resources focusing NSCLC
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Explore our new #LungCancer Resource Center with free access to the latest research and case studies. https://t.co/6jpaAyZDPk #MedTwitter #cancer https://t.co/wgqJPLuYc2
-
-
Mashup Score: 1Neoadjuvant Atezolizumab in Stage IB/IIIB Resectable Lung Cancer - 3 year(s) ago
Neoadjuvant atezolizumab was well-tolerated by patients with stage IB-IIIB lung cancer, according to the primary analysis of the Lung Cancer Mutation Consortium (LCMC) 3 study. “The LCMC3 study is a unique trial in that it is the largest monotherapy trial of checkpoint inhibition in resectable non-small cell lung cancer (NSCLC),” noted Jay M. Lee, MD, from the UCLA Medical Center, who presented…
Source: know.lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Neoadjuvant Atezolizumab in Stage IB/IIIB Resectable #LungCancer https://t.co/aiQh4FUlgl #cancertreatment #medtwitter via @UCLAHealth https://t.co/z1zWDLVwCh
-
ICYMI: New study provides complete overview of biomarker testing, spanning multiple treatment lines in a single cohort of patients with Non-Small Cell #LungCancer https://t.co/RPjlGHZavf #cancer #genetics via @UniMelb https://t.co/BVm2kmtZui